DiscoveRx
成立于2000年的 DiscoveRx 是一家私人持股,風險投資支持的公司,總部設在加州弗里蒙特,在英格蘭伯明翰設立辦事處。公司率先發現beta-糖苷酶片段互補在生物化學和以細胞為基礎的實驗中對研發的作用,在這方面擁有豐富的知識產權。DiscoveRx 致力于開發和新型方法商業化,用以研究 Gapers,室壁不隨意運動和其他主要的藥物靶標類。許多創新產品在全球制藥和生物技術新藥篩選實驗室中廣泛應用
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, California and Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation (EFC) in HitHunter? biochemical and PathHunter? cell based assays for discovery research. In addition to the EFC platform, DiscoveRx also holds extensive intellectual property for its second core technology, an in vitrobinding assay platform called KINOMEscan?. Utilizing these two proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of GPCR, Kinase, and NHR assay solutions for drug discovery research. Many of DiscoveRx's innovative solutions have been widely adopted in pharmaceutical, academic and biotechnology laboratories worldwide.